Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment Publisher Pubmed



Afshari F1 ; Soleymanjahi S2, 3, 4 ; Keshavarzfathi M1, 5, 6 ; Roviello G7, 8 ; Rezaei N6, 9, 10
Authors

Source: Immunotherapy Published:2019


Abstract

Gastric cancer (GC) is the second leading cause of cancer-related death world-wide. Despite improvements in prevention, early detection and various therapeutic options, the prognosis is still poor. GC is often diagnosed at an advanced stage with survivals less than 1 year. Chemotherapy as the mainstay of treatment in advanced stage is not of notable advantages, underlining the need for novel more effective therapeutic options. Based on current knowledge of molecular and cellular mechanisms, a number of novel biologic approaches such as monoclonal antibodies have been recently introduced for cancer treatment that mainly affect the immune system or target signaling pathways playing role in cancer and metastasis development. In this review, various monoclonal antibodies for GC therapy were explained. © 2019 2019 Future Medicine Ltd.
Related Docs
View other Related Docs
1. Immunotherapy of Gastric and Esophageal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
2. Tumor Immunology, Clinical Immunology (2022)
3. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (6)
Mahmood Naderi (2)
Other Related Docs
4. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
5. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
6. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
7. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
8. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
9. Msln (Mesothelin), Antxr1 (Tem8), and Muc3a Are the Potent Antigenic Targets for Car T Cell Therapy of Gastric Adenocarcinoma, Journal of Cellular Biochemistry (2019)
10. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
11. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
12. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
13. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
14. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
15. Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma: A Systematic Review and Meta-Analysis of Efficacy and Review of Characteristics, Expert Review of Anticancer Therapy (2023)
16. Anti-Tumor Activity of Neratinib, a Pan-Her Inhibitor, in Gastric Adenocarcinoma Cells, European Journal of Pharmacology (2019)
17. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
18. Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity, IUBMB Life (2021)
19. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)
20. Antxr1 (Tem8) Overexpression in Gastric Adenocarcinoma Makes the Protein a Potential Target of Immunotherapy, Cancer Immunology# Immunotherapy (2019)